Navigation Links
GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
Date:10/17/2007

SPOKANE, Wash., Oct. 17 /PRNewswire/ -- GenPrime, Inc. a leading provider of rapid microbial analysis technologies, has initiated multi-site clinical trials of its Bacterial Contamination Test for Platelets(TM). The test is a rapid QC device for detecting the presence of aerobic and anaerobic bacteria commonly found in contaminated platelets. The trial will generate data for filing a 510 (K) pre-market notification with the Food and Drug Administration (FDA).

"Undetected bacterial contaminants in platelets tested by culture, dipsticks and other current methods remain a significant source of sepsis and associated patient mortality and morbidity in transfusion medicine," said Buck Somes, chief executive officer of GenPrime. "We believe our technology will offer a practical and rapid solution to further mitigate this problem."

Currently, over 10 million platelet units are transfused annually into patients worldwide. It is estimated by transfusion medicine experts that as many as 1 in 2000 of these units are contaminated with bacteria. While culture based tests, which can take two to three days before results are available, have reduced the chances of contaminated platelets being infused, septic reactions continue to be reported. Traditional rapid tests such as dipsticks, staining and microscopy are highly unreliable. There remains an unmet need in the transfusion industry for a sensitive, rapid, and reliable test that is user friendly and can provide accurate, objective results.

Based on a novel, easy to use, proprietary lateral flow technology platform, GenPrime's Bacterial Contamination Test for Platelets(TM) is designed to detect all 15 organisms known to contaminate platelets. Additionally GenPrime has developed an automated test reader and software for objective result analysis and data collection. The company has completed optimization, scale-up and pre-clinical studies of the test and expects to complete the clinical trial and file the 510(K) pre-market submission to the FDA in early 2008.

For additional information, contact GenPrime, Inc., 157 South Howard, Suite 605 Spokane, WA 99201 USA, Toll Free: 1.866.624.9855, Ph: 509.624.9855, info@genprime.com

About GenPrime, Inc.

GenPrime is committed to becoming the leading provider of innovative technologies for a secure and healthy world. It currently provides products to the homeland security, and fermentation sciences industries. The Company is currently gearing up for its largest product launch yet, a highly sought after bacterial test for blood products in the healthcare and transfusion services industries. http://www.genprime.com


'/>"/>
SOURCE GenPrime, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
8. The Power of External Influence on Our Lives
9. Demonstrations by staff in medical college against violence by external agencies
10. External Catheters Linked with decreased UTI Risk in Men
11. Corneal infections Linked to External Contamination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology: